EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors

Hongfu Lu iD, Deheng Sun, Zhen Wang, Hui Cui, Lihua Min, Haoyu Zhang, Yihong Zhang, Jianping Wu, Xin Cai, Xiao Ding iD, Man Zhang, Alex Aliper iD und 2 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c01616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Hongfu Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Drug Design, Antineoplastic Agents, Protein Kinase Inhibitors, Cyclin-Dependent Kinases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinases 12 and 13 (CDK12/13) safeguard genomic integrity by preferentially regulating gene expression in the DNA damage response (DDR). The CDK12/13-mediated upregulation of DDR genes and pathways significantly contributes to both tumorigenesis and the development of resistance to antitumor therapies. Thus, the functional inhibition of CDK12/13 offers an attractive strategy to combat carcinogenesis, particularly for refractory and treatment-resistant cancers. Here, we report the discovery of compound 12b as a novel, potent, orally available covalent CDK12/13 dual inhibitor with a promising safety profile and robust in vivo antitumor properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAntineoplastic AgentsProtein Kinase InhibitorsCyclin-Dependent KinasesHumansAnimalsAdministration, OralMiceStructure-Activity RelationshipCell Line, TumorNeoplasmsCell ProliferationRatsFemale

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsCyclin-Dependent KinasesCDK12 protein, human

Autor:innen und Institutionen

  • Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
  • Insilico Medicine AI Ltd, Masdar City, Abu Dhabi 145748, UAE.
  • Insilico Medicine Hong Kong Ltd, Hong Kong Science and Technology Park, Hong Kong 999077, China.

ORCID-Profile: Hongfu Lu, Xiao Ding, Alex Aliper, Feng Ren, Alex Zhavoronkov

Zitieren

APA

Lu, H., Sun, D., Wang, Z., Cui, H., Min, L., Zhang, H., Zhang, Y., Wu, J., Cai, X., Ding, X., Zhang, M., Aliper, A., Ren, F., & Zhavoronkov, A. (2025). Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01616

Vancouver

Lu H, Sun D, Wang Z, Cui H, Min L, Zhang H, et al. Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01616

BibTeX
@article{Lu2025,
  author = {Lu, Hongfu and Sun, Deheng and Wang, Zhen and Cui, Hui and Min, Lihua and Zhang, Haoyu and Zhang, Yihong and Wu, Jianping and Cai, Xin and Ding, Xiao and Zhang, Man and Aliper, Alex and Ren, Feng and Zhavoronkov, Alex},
  title = {Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c01616}
}
Kostenlos starten →